Global PCOS Drugs Market 2014-2018

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Competitive Analysis of Marketed Products
08. Pipeline Snapshot
09. Rate of Incidence and Prevalence
09.1.1 Americas
09.1.2 Europe
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Vendors Analysis 2013
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Sanofi SA
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Business Segmentation
19.1.4 Revenue by Business Segmentation
19.1.5 Revenue Comparison 2012 and 2013
19.1.6 Sales by Geography
19.1.7 Business Strategy
19.1.8 Key Developments
19.1.9 SWOT Analysis
19.1.10 Strengths
19.1.11 Weakness
19.1.12 Opportunities
19.1.13 Threats
19.2 Bristol Myers Squibb Co.
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Key Product Offerings
19.2.4 Sales by Geography
19.2.5 Business Strategy
19.2.6 Key Information
19.2.7 SWOT Analysis
19.2.8 Strengths
19.2.9 Weaknesses
19.2.10 Opportunities
19.2.11 Threats
19.3 Novartis A.G.
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.4 SWOT Analysis
19.4.1 Strengths
19.4.2 Weaknesses
19.4.3 Opportunities
19.4.4 Threats
19.5 Teva Pharmaceutical Inc.
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison  2012 and 2013
19.5.6 Revenue Segmentation by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
19.5.10 Strengths
19.5.11 Weakness
19.5.12 Opportunities
19.5.13 Threats
19.6 Merck & Co. Inc.
19.6.1 Key Facts
19.6.2 Business Description
19.6.3 Business Segmentation
19.6.4 Revenue by Business Segmentation
19.6.5 Revenue Comparison 2012 and 2013
19.6.6 Sales by Geography
19.6.7 Business Strategy
19.6.8 Key Developments
19.6.9 SWOT Analysis
19.6.10 Strengths
19.6.11 Weaknesses
19.6.12 Opportunities
19.6.13 Threats
20. Other Reports in this Series